Literature DB >> 9854683

Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.

E Arvat1, B Maccagno, J Ramunni, F Broglio, F Lanfranco, R Giordano, A Benso, R Deghenghi, E Ghigo.   

Abstract

Hexarelin (HEX) is a synthetic GH-secretagogue (GHS) which acts on specific receptors either at the pituitary or the hypothalamic level to stimulate GH release both in animal and in man. Like other GHS, HEX possesses also PRL-, ACTH- and cortisol (F)-releasing activity but the mechanisms underlying these effects are even less clear. On the other hand, galanin (GAL) and serotonin play an important role in the neural control of GH, PRL and ACTH secretion both in animal and in man. In order to study the interaction between HEX and GAL and to verify whether serotoninergic mechanisms underly the endocrine effects of GHS, in 12 normal young volunteers (24-30 yr) the following tests were performed: group A (N = 5), HEX (2.0 micrograms/kg i.v. at 0 min), GAL (15.0 micrograms/kg i.v. from 0 to 60 min) and HEX + GAL; group B (N = 7), HEX alone and preceeded by cyproeptadine (CYPRO, 8 mg os at -60 min). In group A, the GH response to HEX (1204.2 +/- 312.9 micrograms*min/L) was higher (p < 0.05) than that to GAL alone (305.6 +/- 35.5 micrograms*min/L) and was not modified by GAL co-administration (1021.8 +/- 249.9 micrograms*min/L). PRL secretion was increased to the same extent by HEX and GAL (507.9 +/- 81.1 and 743.0 +/- 164.7 micrograms*min/L) which showed no interaction (603.5 +/- 75.7 micrograms*min/L). HEX elicited an increase in both ACTH and F secretion (924.5 +/- 169.7 pg*min/ml and 6131.3 +/- 616.6 micrograms*min/L) while GAL had no effect when given alone (759.5 +/- 185.5 pg*min/ml and 5350.3 +/- 755.6 micrograms*min/L) and did not modify the effect of HEX (891.3 +/- 159.2 pg*min/ml and 5877.8 +/- 554.4 micrograms*min/L). In group B, the GH response to HEX (1636.4 +/- 267.5 micrograms*min/L) was blunted by CYPRO (1164.8 +/- 212.3 micrograms*min/L) but this difference did not attained statistical significance. On the other hand, CYPRO did not modify the HEX-induced PRL (599.5 +/- 129.2 vs 638.9 +/- 131.9 micrograms*min/L), ACTH (1282.8 +/- 222.0 vs 1330.2 +/- 347.0 pg*min/ml) and F response (4738.3 +/- 355.3 vs 4580.9 +/- 857.3 micrograms*min/L). Our present data demonstrate that Hexarelin has no interaction with galanin; thus thereotically, the stimulatory effect of GHS on GH and PRL secretion could involve, at least partially, a galanin-mediated mechanism. On the other hand, our data demonstrate that serotonin does not mediate the stimulatory effect of GHS on PRL, ACTH and cortisol; the intrinsic anticholinergic property of cyproeptadine could account for the trend toward its blunting effect on the GH response to Hexarelin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854683     DOI: 10.1007/BF03350797

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

1.  Galanin inhibits ACTH release in vitro and can be demonstrated immunocytochemically in dispersed corticotrophs.

Authors:  V Cimini
Journal:  Exp Cell Res       Date:  1996-11-01       Impact factor: 3.905

Review 2.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

3.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

4.  Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors.

Authors:  Y de Keyzer; F Lenne; X Bertagna
Journal:  Eur J Endocrinol       Date:  1997-12       Impact factor: 6.664

5.  Morphological evidence for a galanin-opiate interaction in the rat mediobasal hypothalamus.

Authors:  T L Horvath; S P Kalra; F Naftolin; C Leranth
Journal:  J Neuroendocrinol       Date:  1995-08       Impact factor: 3.627

6.  Physiological role of galanin in the regulation of anterior pituitary function in humans.

Authors:  A Giustina; M Licini; M Schettino; M Doga; G Pizzocolo; A Negro-Vilar
Journal:  Am J Physiol       Date:  1994-01

7.  The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors.

Authors:  E F Adams; B Petersen; T Lei; M Buchfelder; R Fahlbusch
Journal:  Biochem Biophys Res Commun       Date:  1995-03-17       Impact factor: 3.575

8.  Enhanced prolactin responsiveness to galanin in patients with Cushing's disease.

Authors:  C Invitti; F Pecori Giraldi; A Tagliaferri; M Scacchi; A Dubini; F Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

9.  Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; L Di Vito; L Gianotti; F Broglio; A Benso; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1998-05       Impact factor: 4.914

10.  Effect of human galanin on growth hormone prolactin, and antidiuretic hormone secretion in normal men.

Authors:  Y Murakami; K Ohshima; T Mochizuki; N Yanaihara
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

View more
  5 in total

1.  The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

Authors:  J Bellone; S Bellone; G Aimaretti; M R Valetto; C Baffoni; G Corneli; C Origlia; E Arvat; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

2.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

3.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Del Rio; E Arvat; M F Boghen; R Deghenghi; G Muccioli; H Ong; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

4.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

Review 5.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.